XML 67 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Segment Data (Tables)
 3 Months Ended
Mar. 27, 2020
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Reportable Segment
Selected information by reportable segment was as follows:

Three Months Ended

March 27,
2020
 
March 29,
2019
Net sales:
 
 
 
Specialty Brands
$
490.6

 
$
604.2

Specialty Generics
175.2

 
186.4

Net sales
$
665.8

 
$
790.6

Operating (loss) income:
 
 
 
Specialty Brands
$
212.2

 
$
275.5

Specialty Generics
48.3

 
24.4

Segment operating income
260.5

 
299.9

Unallocated amounts:
 
 
 
Corporate and unallocated expenses (1)          
(66.5
)
 
(45.8
)
Intangible asset amortization
(197.6
)
 
(222.8
)
Restructuring and related charges, net
1.8

 
(4.2
)
Separation costs (2)
(21.3
)
 
(11.7
)
Opioid-related litigation settlement (3)
16.8

 
—

Operating (loss) income
$
(6.3
)
 
$
15.4



(1)
Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.
(2)
These costs, which are included in SG&A expenses, primarily relate to professional fees, incremental costs incurred to build out the corporate infrastructure of the previously planned spin-off of the Company's Specialty Generics segment, costs incurred as the Company works to resolve opioid uncertainties, as well as rebranding initiatives associated with the Specialty Brands ongoing transformation.
(3)
Represents the change in the Settlement Warrants' fair value. Refer to Note 12 for further information regarding the valuations of the Settlement Warrants.
Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's reportable segments were as follows:
 
Three Months Ended
 
March 27,
2020
 
March 29,
2019
Acthar Gel
$
167.6

 
$
223.9

INOmax
141.7

 
151.1

Ofirmev
74.9

 
95.6

Therakos
63.7

 
61.8

Amitiza (1)
41.1

 
53.0

Other (2)
1.6

 
18.8

Specialty Brands
490.6

 
604.2

 
 
 
 
Hydrocodone (API) and hydrocodone-containing tablets
26.5

 
17.4

Oxycodone (API) and oxycodone-containing tablets
16.9

 
16.5

Acetaminophen (API)
44.1

 
46.2

Other controlled substances
83.6

 
94.2

Other
4.1

 
12.1

Specialty Generics
175.2

 
186.4

Net sales
$
665.8

 
$
790.6


(1)
Amitiza consists of both product net sales and royalties. Refer to Note 2 for further details on Amitiza's revenues.
(2)
The three months ended March 29, 2019 includes $12.4 million of net sales related to BioVectra prior to the completion of the sale of this business in November 2019.